GlycoMimetics
Manufacturing · Maryland, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
9708 Medical Center Dr, Rockville, Maryl...Phone Number
(240) 243-1201Website
www.glycomimetics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About GlycoMimetics
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville,...Explore more
GlycoMimetics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GlycoMimetics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if GlycoMimetics had a recent Job posting/layoffs
Check if GlycoMimetics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once GlycoMimetics has new funding data
Congratulate Masked Content for being promoted to Masked Content at GlycoMimetics
Check out if GlycoMimetics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on GlycoMimetics recently announced quarterly report
Product Launch: Get notified when GlycoMimetics launches new products
GlycoMimetics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined GlycoMimetics as Masked Content
Find more new buyers
Compare Similar Companies to GlycoMimetics
Compare insights from companies similar to GlycoMimetics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
GlycoMimetics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
GlycoMimetics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about GlycoMimetics.
GlycoMimetics financials insights
Gather financial insights about GlycoMimetics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2004
Series A
$9.6M
2006
Series B
$15.4M
2009
Series C
$38M
2014
Stock Offering
$57.4M
2015
Corporate Investment
$20M
2016
Stock Offering
$20M
2018
Stock Offering
$128.4M
GlycoMimetics Tech Stack
A closer look at the technologies used by GlycoMimetics
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Earnings
Earnings
GlycoMimetics News & Media
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of GlycoMimetics, Inc. (NasdaqGM: GLYC) and Crescent Biopharma, Inc. Pursuant to the terms of the agreement, shareholders of GlycoMimetics will own approximately 3.1% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether theGlycomimetics, Inc. Announces Cessation of Brian Hahn as Chief Financial Officer, No Later ...
On January 29, 2025, Mr. Brian Hahn, the GlycoMimetics, Inc.?s Chief Financial Officer, notified the Company?s board of directors of his intent to cease his respective employment with the Company no...GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, California, on December 7-10, 2024. ASH Annual Meeting abstracts may be accessed online at www.hematology.org. Details of GlycoMimetics presentations are as follows (GlycoMimetics Announces Merger with Crescent Biopharma - Yahoo Finance
GlycoMimetics ( (GLYC) ) has issued an update. GlycoMimetics, Inc. has announced a merger with Crescent Biopharma, aiming to enhance their presence in the biopharma sector. This merger, structured as a tax-free reorganization, will result in Crescent’s shareholders owning a significant majority of the combined entity. The transaction includes a substantial private placement of $200 million to support future growth and development. Both companies’ boards have approved the merger, expected to clos
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GlycoMimetics
Sign Up For FreeTo access detailed company insights
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the tr... Read More
